Triple Negative Breast Neoplasms
"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
Descriptor ID |
D064726
|
MeSH Number(s) |
C04.588.180.788 C17.800.090.500.788
|
Concept/Terms |
Triple Negative Breast Neoplasms- Triple Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Neoplasms
- ER Negative PR Negative HER2 Negative Breast Neoplasms
- Triple-Negative Breast Cancer
- Breast Cancer, Triple-Negative
- Breast Cancers, Triple-Negative
- Triple-Negative Breast Cancers
- Triple-Negative Breast Neoplasm
- Breast Neoplasm, Triple-Negative
- Breast Neoplasms, Triple-Negative
- Triple Negative Breast Neoplasm
- Triple-Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Cancer
- ER Negative PR Negative HER2 Negative Breast Cancer
- Triple Negative Breast Cancer
|
Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".
This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2014 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2016 | 2 | 0 | 2 |
2017 | 3 | 0 | 3 |
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.
-
CircRAD54L2 promotes triple-negative breast cancer progression by regulating the miR-888 family/PDK1 axis. Life Sci. 2023 Jan 01; 312:121128.
-
Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020 12 11; 11(12):1052.
-
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019 02 21; 21(1):29.
-
MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat. 2018 Aug; 170(3):477-486.
-
Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11).
-
CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget. 2017 Jun 13; 8(24):38294-38308.
-
GROa overexpression drives cell migration and invasion in triple negative breast cancer cells. Oncol Rep. 2017 Jul; 38(1):21-30.
-
Chemotherapeutic Vulnerability of Triple-negative Breast Cancer Cell-derived Tumors to Pretreatment with Vernonia amygdalina Aqueous Extracts. Anticancer Res. 2016 Aug; 36(8):3933-43.
-
Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis. BMC Cancer. 2016 07 29; 16:559.
-
Estrogen Receptor-ß and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90.